2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…2018 American Transplant Congress
A Novel Combined Formula to Direct Optimal Immunosuppressive Drug Exposure in Renal Transplant Recipients
Purpose: The most widely used maintenance immunosuppressive combination after kidney transplantation is tacrolimus (TAC) and mycophenolic acid (MPA). The utility of therapeutic drug monitoring for…2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report
Adherence to immunosuppressant regimen is crucial for graft survival and usually inversely related to the dose frequency. Similar efficacy and safety profile has been approved…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »